Treatment of Pulmonary Metastases in EGFR-Mutant NSCLC and Oncogene-Driven Tumors with Oligoprogression During Systemic Therapy
When metastatic cancer progresses at only a limited number of pulmonary sites while the rest of the disease remains controlled on systemic treatment — a pattern called oligoprogression — a distinct management strategy applies. This situation arises most commonly in oncogene-driven tumors, including EGFR-mutant non-small cell lung cancer.
Clinical Scenario
Oligoprogressive disease occurs when the failure of initial systemic treatment is represented by a limited number of sites rather than widespread progression. These isolated lesions may harbour cell clones resistant to the ongoing systemic agent, yet the rest of the disease remains under control. This pattern has been most frequently described in oncogene-driven tumors such as EGFR-mutant NSCLC, and the limited extent of progression may make these sites suitable for loco-regional intervention.
Approach (partial)
Management focuses on a local ablative strategy directed at the progressing pulmonary site(s), combined with continuation of the ongoing systemic agent — the full protocol details the preferred modality, patient selection, and the complete treatment algorithm.
References
DOI: 10.21037/asj-21-81
- Oligoprogressive disease includes situations in which the tumor is not limited to a single or few metastatic lesions, but the failure of the initial systemic treatment is represented by a limited number of sites, potentially suitable for loco-regional approaches.
- Notably, this occurrence has been largely described in oncogenic-driven tumors, such as EGFR-mutant NSCLC.
- The development of new isolated lesions in a disease which is otherwise under control during systemic treatment creates a good opportunity for loco-regional approaches including surgery and radiation therapy, as such treatments might succeed in ablating a lesion characterized by cell clones resistant to the systemic therapy, hence potentially delaying the occurrence of actual, systemic progression requiring the switch to a subsequent line of therapy.
- In a study of ablative treatments in association with TKIs for NSCLC, patients receiving crizotinib for ALK-rearranged NSCLC (n=38) or erlotinib for EGFR-mutant NSCLC (n=27) were treated with local ablative treatments (either surgery or radiotherapy), resulting in approximately 6 months of additional disease control.
- The occurrence of oligoprogression can be treated with local approaches (in this case, preferably radiation therapy).